Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Archives of Neurology

• Publication date

  2008-06-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/archneur.65.6.762PMID 18541796
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Simvastatin treatment prolongs the survival of scrapie-infected mice

  2007cited by this paper
• Chemokine ligand 2 (CCL2) induces migration and differentiation of subventricular zone cells after stroke

  2007cited by this paper
• The prion protein and lipid rafts (Review)

  2006cited by this paper
• Immunological memory stabilizing autoreactivity.

  2006cited by this paper
• Antioxidative actions of statins: potential mechanisms for antiathersclerotic effects.

  2006cited by this paper
• Simvastatin prolongs survival times in prion infections of the central nervous system.

  2006cited by this paper
• The role of rafts in the fibrillization and aggregation of prions.

  2006cited by this paper
• Suppressive effect of simvastatin on interferon-beta-induced expression of CC chemokine ligand 5 in microglia.

  2006cited by this paper
• The prion protein and lipid rafts.

  2006cited by this paper
• Statins in the treatment of central nervous system autoimmune disease.

  2006cited by this paper
• Statins — a cure-all for the brain?

  2005cited by this paper
• Microglia activated by IL-4 or IFN-g differentially induce neurogenesis and oligodendrogenesis from adult stem / progenitor cells

  2005cited by this paper
• Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases.

  2005cited by this paper
• Anchorless Prion Protein Results in Infectious Amyloid Disease Without Clinical Scrapie

  2005cited by this paper
• Lipid rafts and membrane dynamics

  2005cited by this paper
• Clinical implications for statin pleiotropy

  2005cited by this paper
• Neuroprotective properties of statins.

  2005cited by this paper
• Role of inflammation in neurodegenerative diseases

  2005cited by this paper
• MinireviewBirth of a Prion : Spontaneous Generation Revisited

  2005cited by this paper
• Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism.

  2005cited by this paper
• Pathogenesis of prion diseases

  2005cited by this paper
• Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity*

  2004cited by this paper
• Transcriptional regulation of antigen presentation.

  2004cited by this paper
• Identification of Differentially Expressed Genes in Scrapie-Infected Mouse Brains by Using Global Gene Expression Technology

  2004cited by this paper
• Immunohistochemical study of microglia in the Creutzfeldt-Jakob diseased brain

  2004cited by this paper
• The potential therapeutic role of statins in central nervous system autoimmune disorders

  2003cited by this paper
• T Cells Infiltrate the Brain in Murine and Human Transmissible Spongiform Encephalopathies

  2003cited by this paper
• Protective autoimmunity against the enemy within: fighting glutamate toxicity.

  2003cited by this paper
• Atypical inflammation in the central nervous system in prion disease

  2002cited by this paper
• Cholesterol, lipid rafts, and disease.

  2002cited by this paper
• Lymphocyte migration into the central nervous system: implication of ICAM-1 signalling at the blood-brain barrier.

  2002cited by this paper
• Synaptic pathology and cell death in the cerebellum in Creutzfeldt-Jakob disease

  2002cited by this paper
• Conversion of raft associated prion protein to the protease‐resistant state requires insertion of PrP‐res (PrPSc) into contiguous membranes

  2002cited by this paper
• Pharmacology and clinical experience with simvastatin

  2001cited by this paper
• Prion-induced neuronal damage--the mechanisms of neuronal destruction in the subacute spongiform encephalopathies.

  2001cited by this paper
• Reconstitution of Prion Infectivity from Solubilized Protease-resistant PrP and Nonprotein Components of Prion Rods*

  2001cited by this paper
• Chemokines Released from Astroglia by Vasoactive Intestinal Peptide: Mechanism of Neuroprotection from HIV Envelope Protein Toxicity

  2000cited by this paper
• Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie‐infected murine hippocampus

  2000cited by this paper
• Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion Protein in Infected Cultures

  2000cited by this paper
• Statins as a newly recognized type of immunomodulator

  2000cited by this paper
• Sphingolipid Depletion Increases Formation of the Scrapie Prion Protein in Neuroblastoma Cells Infected with Prions*

  1999cited by this paper
• 13 Inherited Prion Diseases

  1999cited by this paper
• Microglial Activation Varies in Different Models of Creutzfeldt-Jakob Disease

  1999cited by this paper
• Science, medicine, and the future: Parkinson's disease.

  1999cited by this paper
• Creutzfeldt-Jakob disease

  1998cited by this paper
• COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform

  1997cited by this paper
• Transmission of the BSE Agent to Mice in the Absence of Detectable Abnormal Prion Protein

  1997cited by this paper
• COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform.

  1997cited by this paper
• Characterization of Detergent-insoluble Complexes Containing the Cellular Prion Protein and Its Scrapie Isoform*

  1997cited by this paper
• Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains.

  1996cited by this paper
• Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform [published erratum appears in J Cell Biol 1995 Jul;130(2):501]

  1995cited by this paper
• Inherited prion diseases.

  1994cited by this paper
• In Vivo and in Vitro Blood–Brain Barrier Transport of 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors

  1994cited by this paper
• Mice devoid of PrP are resistant to scrapie.

  1993cited by this paper
• Possible involvement of interleukin-1 in ischemic brain edema formation.

  1992cited by this paper
• Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface.

  1992cited by this paper
• Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease.

  1991cited by this paper
• Mutation in codon 200 of scrapie amyloid precursor gene linked to Creutzfeldt-Jakob disease in Sephardic Jews of Libyan and non-Libyan origin.

  1990cited by this paper
• Immunoregulation of cells within the central nervous system.

  1988cited by this paper
• Scrapie prion protein contains a phosphatidylinositol glycolipid.

  1987cited by this paper
• Molecular properties, partial purification, and assay by incubation period measurements of the hamster scrapie agent.

  1980cited by this paper
• Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase.

  1978cited by this paper
• Creutzfeldt-Jakob Disease: Focus among Libyan Jews in Israel

  1974cited by this paper

• Treatment with efavirenz extends survival in a Creutzfeldt-Jakob disease model by regulating brain cholesterol metabolism

  2025cites this paper
• Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington’s disease and Prion diseases

  2025cites this paper
• What is the role of lipids in prion conversion and disease?

  2023cites this paper
• Cholesterol and its reciprocal association with prion infection

  2022cites this paper
• Prion therapeutics: Lessons from the past

  2022cites this paper
• The first non-prion pathogen identified: neurotropic influenza virus

  2022cites this paper
• Virus Infection, Genetic Mutations, and Prion Infection in Prion Protein Conversion

  2021cites this paper
• The Combined Use of Phenothiazines and Statins Strongly Affects Doxorubicin-Resistance, Apoptosis, and Cox-2 Activity in Colon Cancer Cells

  2019cites this paper
• Neuroinflammation, Microglia, and Cell-Association during Prion Disease

  2019cites this paper
• Identifying therapeutic targets and treatments in model systems.

  2018cites this paper
• Pharmacological activation of autophagy favors the clearing of intracellular aggregates of misfolded prion protein peptide to prevent neuronal death

  2018cites this paper
• Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.

  2017cites this paper
• Plasma cholesterol level determines in vivo prion propagation

  2017cites this paper
• A loss-of-function approach to investigate the role of cholesterol in prion replication

  2016cites this paper
• Convection-Enhanced Delivery of AAV2-PrPshRNA in Prion-Infected Mice

  2014cites this paper
• Cholesterol Balance in Prion Diseases and Alzheimer’s Disease

  2014cites this paper
• Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic CJD.

  2014cites this paper
• Prion Infection Impairs Cholesterol Metabolism in Neuronal Cells*

  2013cites this paper
• Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease

  2013cites this paper
• Animal models for testing anti-prion drugs.

  2013cites this paper
• Neurodegeneration Induced by Clustering of Sialylated Glycosylphosphatidylinositols of Prion Proteins*

  2012cites this paper
• A genome-wide survey for prion-regulated miRNAs associated with cholesterol homeostasis

  2012cites this paper
• Copper is toxic to PrP-ablated mice and exacerbates disease in a mouse model of E200K genetic prion disease.

  2012cites this paper
• Accumulation and aberrant composition of cholesteryl esters in Scrapie-infected N2a cells and C57BL/6 mouse brains

  2011cites this paper
• Fatal Prion Disease in a Mouse Model of Genetic E200K Creutzfeldt-Jakob Disease

  2011cites this paper
• Age-related alterations affect the susceptibility of mice to prion infection.

  2011cites this paper
• Heat shock proteins: therapeutic drug targets for chronic neurodegeneration?

  2010cites this paper
• Cholesterol, Alzheimer's disease, prion disorders: a ménage à trois?

  2010cites this paper
• Cellular cholesterol enrichment prevents prion peptide-induced neuron cell damages.

  2010cites this paper
• Inhibition of cholesterol recycling impairs cellular PrPSc propagation

  2009cites this paper
• Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice.

  2009cites this paper
• Therapeutic interventions ameliorating prion disease

  2009cites this paper
• Oral pravastatin prolongs survival time of scrapie-infected mice.

  2009cites this paper
• Neuroinflammation in prion diseases: concepts and targets for therapeutic intervention.

  2009cites this paper